Would you accept 99.1% on mazdutide from QST without a content assay?

Setup, so nobody has to ask: 99.1% · mazdutide · QST.

I would like to set this up properly once, rather than adjust it repeatedly.

My budget is real but not tight, and my tolerance for uncertainty is low.

How would you structure this, and what thresholds would you set in advance?

Start from what the detector sees, because that tells you what the number means.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

edited 15 Sept 2024 by deamidation_watch — expanded the table to cover the lower concentration

Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Concretely, mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

If you are ranking vendors, specify a method and have all samples tested at the same place.

Identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

Compare purity within a single laboratory on the same method, never across laboratories.

The relevant detail is that the short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.